Background and Purpose-To test whether changes in plasma tissue factor pathway inhibitor (TFPI) levels or activated protein C resistance (normalized activated protein C resistance ratio [nAPCsr]) modify the increased risk of ischemic stroke due to postmenopausal hormone therapy. Methods-Nested case-control study of 455 cases of ischemic stroke and 565 matched control subjects in the Women's Health Initiative trials of postmenopausal hormone therapy. Results-Baseline free TFPI was associated with ischemic stroke risk (OR per SD increase, 1.17; 95% CI, 1.01-1.37; Pϭ0.039), but baseline nAPCsr was not (OR per SD increase, 0.89; 95% CI, 0.75-1.05; Pϭ0.15). Baseline TFPI levels and nAPCsr did not modify the effect of postmenopausal hormone therapy on ischemic stroke. Treatment-induced mean changes of Ϫ28% in free TFPI and ϩ65% in nAPCsr did not change the risk of ischemic stroke (interaction Pϭ0.452 and 0.971, respectively). In subgroup analyses, baseline nAPCsr was inversely associated with lacunar strokes (OR per SD increase, 0.74; 95% CI, 0.57-0.96; Pϭ0.025) and baseline free TFPI interacted with treatment to increase large vessel atherosclerotic strokes (Pϭ0.008). Conclusions-Procoagulant changes in TFPI or nAPCsr do not modify the increased ischemic stroke risk due to postmenopausal hormone therapy.
T he Women's Health Initiative (WHI) trials of showed an increased risk of ischemic stroke for postmenopausal hormone therapy (PHT) compared with placebo. 1, 2 Baseline levels of several hemostatic markers and genotypic Factor V Leiden (FVL) status did not identify women at increased risk of ischemic stroke on PHT in the WHI trials. 3 PHT increased D-dimer and plasmin-antiplasmin levels and decreased fibrinogen and plasminogen activator inhibitor-1, and change in D-dimer interacted with PHT to increase the risk of stroke. 3 The fact that PHT increased the risk of venous thromboembolism in WHI, especially in subjects with FVL, is consistent with a possible role for hemostatic factors in explaining the increased risk of stroke also. 4, 5 Oral PHT increases markers of activated coagulation, reduces coagulation inhibitors, and induces an acquired resistance to the natural anticoagulant activated protein C (APC). [6] [7] [8] [9] Reduction in tissue factor pathway inhibitor (TFPI) and protein S are thought to be important mechanisms underlying the activation of coagulation and acquired protein C resistance associated with oral contraceptives, and both have been implicated in venous thromboembolism. 10 Cross-sectional studies suggest that low levels of TFPI or increased APC resistance may play a role in childhood ischemic stroke, but their roles in adult strokes are unclear. [11] [12] [13] Higher TFPI levels in subjects with subclinical carotid and coronary atherosclerosis and with increased arterial stiffness may reflect endothelial dysfunction. 14 -16 We report the first prospective study of the associations of acquired APC resistance and of TFPI levels with stroke, and we examine whether PHT-induced changes in these factors are associated with stroke risk in the WHI trials. We also examine associations with major subgroups of stroke. MET indicates metabolic equivalents; ECG, electrocardiogram; CVD, cardiovascular disease; BP, body mass index; TFPI, tissue factor pathway inhibitor; nAPCsr, normalized activated protein C resistance ratio.
*The P values quantify the marginal association of each baseline characteristic and biomarker with ischemic stroke and are obtained from logistic regression models in combined trials adjusted for treatment assignment (CEE, CEE placebo, CEEϩMPA, CEEϩMPA placebo) using a 1-df test for association except for the categorical values ethnicity, smoking status, alcohol use, physical activity, and history of hypertension.
†Myocardial infarction, percutaneous coronary intervention, coronary artery bypass grafting, congestive heart failure, angina, stroke, or atrial fibrillation.
Methods
Details of the design, recruitment, randomization, data collection, intervention, and outcomes ascertainment procedures in the WHI PHT trials, including Consolidated Standards of Reporting Trials (CONSORT) diagrams, have been published previously. 3, 17, 18 
Study Population and Interventions
The WHI hormone trials enrolled 27 347 postmenopausal women aged 50 to 79 years from 1993 to 1998 at 40 US clinical centers based on hysterectomy status: 16 608 without hysterectomy in a trial of conjugated equine estrogens plus medroxyprogesterone acetate (CEEϩMPA) and 10 739 with hysterectomy in a trial of CEE alone. Blood specimens were collected at baseline and the 1-year visit. The study was approved by the human subjects review committee at each participating institution, and all participants provided written informed consent. Participants were randomly assigned to take a single daily tablet containing a placebo or active medication: women without hysterectomy took 0.626 mg CEE plus 2.5 mg MPA (Prempro), and women with hysterectomy took 0.625 mg CEE (Premarin). 
Follow-Up and Outcome Ascertainment
Stroke outcomes were identified by semiannual questionnaires followed by review of medical records and classification by stroketrained neurologists blinded to treatment assignment. This report is based on 565 centrally adjudicated strokes with measurements of APC resistance or TFPI at baseline and control subjects matched on age, race, randomization date, hysterectomy status, and self-reported prevalent stroke or transient ischemic attack at baseline. Strokes were classified into ischemic (Nϭ455), hemorrhagic (Nϭ82), other (Nϭ4), cause of death only (Nϭ21), and missing (Nϭ3). Ischemic strokes were subclassified according to the Trial of Org 10172 in Acute Stroke Therapy (TOAST). 19 The major identifiable subgroups were large artery atherosclerosis (Nϭ43), cardioembolism (Nϭ66), and small vessel occlusion (lacune; Nϭ117). The remaining 229 ischemic strokes had insufficient information to make a determination or had Ն2 potential etiologies. TFPI indicates tissue factor pathway inhibitor; nAPCsr, normalized activated protein C resistance ratio; CEE, conjugated equine estrogens; MPA, medroxyprogesterone acetate.
*OR for ischemic stroke compared with control subjects per SD of biomarker (in control subjects) from logistic regression models adjusted for treatment assignment (CEE, CEE placebo, CEEϩMPA, CEEϩMPA placebo), interaction with treatment assignment, age, race, body mass index, waist-hip ratio, smoking, alcohol use, physical activity, diabetes mellitus, prevalent cardiovascular disease (including atrial fibrillation), systolic and diastolic blood pressure, left ventricular hypertrophy on electrocardiogram, use of antihypertensive medications, aspirin, statins, and ever treated for high cholesterol.
†Covariate adjustment for hysterectomy status and as in the preceding footnote. ‡P values are based on logistic regression models in combined trials using a 1-df test for association. Covariate adjustment as in the preceding footnotes. *From logistic regression models adjusted for age, race, body mass index, waist-hip ratio, smoking, alcohol use, physical activity, diabetes mellitus, prevalent cardiovascular disease (including atrial fibrillation), systolic and diastolic blood pressure, left ventricular hypertrophy on electrocardiogram, use of antihypertensive medications, aspirin, statins, and ever treated for high cholesterol.
†P values for the interaction in combined trials of active treatment/placebo X biomarker on ischemic stroke risk based on a 1-df test for biomarkers. Covariate adjustment for hysterectomy status and as in the preceding footnote.
Biomarker Analyses
Blood samples were collected into tubes containing 1.8% sodium citrate and centrifuged within 2 hours at 1300 g for 10 minutes at 4°C and stored at Ϫ70°C. Assays were run in duplicate in single batches including cases and control subjects and 10% blind duplicates within 8 years of collection. The endogenous thrombin potential-based activated protein C resistance test (ETP-based APC resistance test) was performed at the Department of Biochemistry at the University of Maastricht, The Netherlands, as described earlier. 20 The test result is expressed as the ratio of thrombin generation without and with added APC normalized against pooled normal plasma (nAPCsr). In this assay, higher nAPCsr values indicate increasing APC resistance. Total and free TFPI antigen were assayed using the same batch of Asserochrom enzyme-linked immunosorbent assay (Stago) kits for each, and TFPI activity was measured in citrated plasma by an in-house chromogenic substrate activity assay at the Department of Hematology, Oslo University Hospital, Oslo. 21, 22 Inter-and intra-assay coefficients of variation were 3% to 5% and 1% to 3% for all assays. In 150 blind duplicates from the current study, the intraclass correlations for nAPCsr and TFPI (total, free, and activity) were 0.73, 0.83, 0.44, and 0.84, respectively.
Statistical Analyses
The primary analysis tested the hypothesis that PHT-induced increases in APC resistance and reductions in free TFPI levels increase the risk of ischemic stroke. Cases of ischemic stroke (Nϭ455) and all control subjects (Nϭ565) were used to study associations of baseline values with ischemic stroke; associations of change in TFPI values were examined in 317 cases occurring after Year 1 and in 465 control subjects, whereas change in nAPCsr values was examined in 220 cases and 330 control subjects with both baseline and Year 1 values available. Lacunar and nonlacunar ischemic stroke, hemorrhagic stroke, and total stroke were examined in secondary analyses. We combined the trial data because their effects on stroke were similar. 1,2 Sensitivity analyses excluded women not adherent to their study medication 6 months before their stroke.
Biomarkers were examined on a continuous (linear) scale after log transformation for biomarkers that had skewed distributions. We used markers linearly to assess significance but reported ORs and 95% CIs per SD increase. Thus, there was not 1-to-1 correspondence between probability values below 0.05 and CIs for OR not containing 1. For the interaction of change in biomarkers levels from baseline to Year 1, we computed probability values from logistic coefficients for change as a continuous variable but showed ORs by tertiles of change. We also examined whether changes in individual biomarkers were intermediates in the pathway of hormone therapy effects on stroke by comparing regression models with and without terms for biomarker change covariates.
We tested for nominal significance at PϽ0.05 without adjustment for multiple testing. Statistical analyses were performed on SAS statistical software (Version 9; SAS Institute Inc, Cary, NC).
Results
In this case-control data set, PHT compared with placebo yielded overall multivariable-adjusted ORs (95% CI) for total, ischemic, and hemorrhagic stroke of 1.60 (1.23-2.09), 1.81 (1.36 -2.40), and 0.87 (0.52-1.46), respectively. Cases of ischemic stroke were more likely to be smokers, nondrinkers, inactive, diabetic, hypertensive, have left ventricular hypertrophy, or a history of prior cardiovascular disease, higher body mass index, waist-to-hip ratio, and systolic and diastolic blood pressure compared with control subjects (Table 1 ). Due to matching factors, race/ethnicity and age did not differ between cases and control subjects. In unadjusted analyses, baseline free TFPI levels were significantly higher in ischemic stroke cases than control subjects (Pϭ0.002), but total TFPI, TFPI activity, and nAPCsr did not differ between cases and control subjects. In multivariable-adjusted models, baseline free TFPI was positively associated with ischemic stroke (OR per SD increase, 1.17; 95% CI, 1.01-1.37; Pϭ0.037), but baseline nAPCsr was not associated with ischemic stroke (OR per SD increase, 0.89; 95% CI, 0.75-1.05; Pϭ0.15; Table 2 ). Baseline TFPI and nAPCsr did not modify the effect of hormone therapy on stroke risk (Table 3) . . TFPI was correlated with lipoproteins but adding lipoprotein covariates to the models did not alter any results. PHT variably decreased TFPI levels and increased nAPCsr compared with no changes in the placebo group with mean net decreases of Ϫ19%, Ϫ28%, and Ϫ22%, respectively, for total, free, and TFPI activity and an increase of 65% for nAPCsr (Table 4; Figure) . In the subset with known FVL carrier status baseline, mean (SD) nAPCsr values were 4.9 (2.2) in the 25 FVL heterozygotes and 7.2 in the single homozygote compared with a mean of 3.0 (1.9) in noncarriers. Baseline and Year 1 nAPCsr exceeded 2.0 in all but 1 of the heterozygotes; however, their values were overlapped completely by those of known noncarriers.
Change in free TFPI did not modify stroke risk (interaction Pϭ0.452; Table 5 ). Although women in upper and lower tertiles of change in nAPCsr appeared to be at higher risk of ischemic stroke on hormone therapy, the interaction was not significant (interaction Pϭ0.971 in linear models, Pϭ0.38 in quadratic CEE indicates conjugated equine estrogens; MPA, medroxyprogesterone acetate; IQR, interquartile range; TFPI, tissue factor pathway inhibitor; nAPCsr, normalized activated protein C resistance ratio.
*P values are from a paired t test (per participant) of change in biomarker in combined trials during hormone treatment compared to control adjusted for hysterectomy status, baseline levels of biomarkers, and the same covariates as in Table 3 . models). Models with change in TFPI or nAPCsr added as a covariate showed no evidence that change in these biomarkers mediated the effect of PHT on ischemic stroke risk.
Secondary analyses restricted to adherent participants yielded results similar to those for the overall study. Models comparing the extreme deciles of TFPI or nAPCsr with values below or above the median, respectively, did not yield significant associations with ischemic stroke for baseline values or for change at 1 year. In other secondary analyses, the findings for total stroke were similar in direction and strength to those for ischemic stroke, whereas hemorrhagic stroke showed no evidence of an association with TFPI or nAPCsr. Subtypes of stroke by TOAST criteria indicated that lacunar strokes were inversely associated with baseline nAPCsr (OR, 0.74; 95% CI, 0.57-0.96; Pϭ0.025); however, nAPCsr did not interact with treatment on ischemic stroke. Higher baseline levels of free TFPI were not associated with large artery atherosclerotic strokes but interacted with treatment to increase risk (Pϭ0.008).
Discussion
Although PHT induced substantial increases in nAPCsr and decreases in TFPI, these changes were not related to the increased risks of ischemic stroke observed in the WHI trials. The mechanisms underlying the increased stroke risks on PHT remain elusive, although hemostatic mechanisms remain the most likely culprits with increases in D-dimer implicated in prior analyses of a subset of WHI data. 3 Without knowledge of a mechanism, it is difficult to design strategies to prevent this complication of oral PHT. Transdermal estradiol does not appear to share the prothrombotic potential of oral estrogens with respect to venous thrombosis or stroke, but randomized trial evidence is lacking. 23, 24 The relationships of nAPCsr and TFPI to ischemic stroke risk are complex. Contrary to our hypothesis that reduced anticoagulant function would increase risk of ischemic stroke, in this study, baseline free TFPI levels were higher in cases compared with control subjects, whereas no significant differences were observed for nAPCsr. The findings for TFPI are consistent with previous studies of carotid atherosclerosis, arterial stiffness, and ischemic heart disease. 14 -16,25 Previous case-control studies did not find convincing evidence that FVL is associated with stroke. 26 In the subset of lacunar strokes, nAPCsr values were significantly lower in stroke cases than in control subjects. Lacunar strokes result from pathology of the small perforating arteries supplying the deep subcortical areas of the brain. Previous work has suggested that lacunar arteriopathy may differ from occlusive atherothrombosis of the large arteries responsible for other ischemic strokes and that the risk factor profile of lacunar stroke may differ from that of nonlacunar stroke. 27 Higher free TFPI levels increased the risk of large vessel atherosclerotic stroke due to hormone therapy. However, these subgroup findings may have occurred by chance due to the multiple testing performed. TFPI indicates tissue factor pathway inhibitor; nAPCsr, normalized activated protein C resistance ratio. *P values for interaction in combined trials of active treatment/placebo X change in biomarker adjusting for hysterectomy status, baseline level of biomarkers, and the same covariates as in Table 3 based on 317 cases and 465 control subjects for TFPI and 220 cases and 330 control subjects for nAPCsr. Tertile cut points for change are derived from control subjects.
The 5.7% prevalence of FVL ascertained by genotype is similar to that reported in the literature 9 but nAPCsr did not clearly discriminate FVL carriers from noncarriers. This may be due to high overall nAPCsr values in this study compared with values reported in the literature, making the window for discrimination smaller. The high values are likely caused by the fact that APCsr determined with the ETP-based APC resistance test is normalized by dividing through the APCsr measured in normal pooled plasma. 20 Differences in preanalytical variables such as venipuncture, citrate concentration, centrifugation, plasma handling, and storage of the WHI plasma and the normal pooled plasma used in the laboratory may result in high sensitivity of pooled plasma for APC compared with WHI plasma.
Strengths of the current study include its setting in the context of a randomized controlled clinical trial, which allows for an unbiased assessment of treatment effects on hemostatic factors and stroke. Limitations include the relatively small number of strokes overall and the large number of strokes of undetermined etiology. Only large interactions of treatment with biomarkers could have been detected; however, the primary analysis of interaction by change in biomarker offered no hint of potential effect modification. Another limitation is the variability in the laboratory measurements, especially for free TFPI. Clinical trial participants may differ from the general population and the results may not be generalizable.
We conclude that changes nAPCsr and TFPI in response to PHT do not modify or mediate the increased ischemic stroke risk due to hormone therapy. Higher baseline free TFPI was associated with overall risk of ischemic stroke and with increased risk of large vessel atherosclerotic strokes, but the direction of these associations was the opposite of what one might have expected from studies of venous thromboembolism. Future studies are needed to confirm the apparent protective association of nAPCsr with lacunar stroke and to explore the biology of this association.
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